Hodder, S., Squires, K., Kityo, C., Hagins, D., Avihingsanon, A., Kido, A., . . . Cao, H. (2018). Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women. J Acquir Immune Defic Syndr.
シカゴスタイル引用形Hodder, Sally, et al. "Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women." J Acquir Immune Defic Syndr 2018.
MLA引用形式Hodder, Sally, et al. "Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women." J Acquir Immune Defic Syndr 2018.